Let The Future Start Today: Development Of Better LNP-Based Genetic Medicines

Lipid nanoparticles (LNPs) are effective non-viral vectors, which are widely used delivery vehicles for genetic medicines such as messenger RNA (mRNA). As a result, it is important to understand and limit LNP-related impurities to help ensure genetic product integrity and mitigate risks to patient safety and product efficacy. To keep up with global demand, there is a need to shorten development timelines for gene-based therapeutics and vaccines.

Discover how you can accelerate the time to patients for new vaccines and therapies with innovative, streamlined technology that is quicker and more intuitive.